<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">cancers</journal-id>
<journal-title-group>
<journal-title>Cancers</journal-title>
</journal-title-group>
<issn pub-type="epub">2072-6694</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31979093</article-id>
<article-id pub-id-type="pmc">7072670</article-id>
<article-id pub-id-type="doi">10.3390/cancers12020268</article-id>
<article-id pub-id-type="publisher-id">cancers-12-00268</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenethyl Isothiocyanate Suppresses Stemness in the Chemo- and Radio-Resistant Triple-Negative Breast Cancer Cell Line MDA-MB-231/IR Via Downregulation of Metadherin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nguyen</surname>
<given-names>Yen Thi-Kim</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-12-00268">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moon</surname>
<given-names>Jeong Yong</given-names>
</name>
<xref ref-type="aff" rid="af2-cancers-12-00268">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9393-9516</contrib-id>
<name>
<surname>Ediriweera</surname>
<given-names>Meran Keshawa</given-names>
</name>
<xref ref-type="aff" rid="af2-cancers-12-00268">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4685-3303</contrib-id>
<name>
<surname>Cho</surname>
<given-names>Somi Kim</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-12-00268">1</xref>
<xref ref-type="aff" rid="af2-cancers-12-00268">2</xref>
<xref ref-type="aff" rid="af3-cancers-12-00268">3</xref>
<xref ref-type="corresp" rid="c1-cancers-12-00268">*</xref>
</contrib>
</contrib-group>
<aff id="af1-cancers-12-00268"><label>1</label>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 63243, Korea; <email>am20189301@jejunu.ac.kr</email></aff>
<aff id="af2-cancers-12-00268"><label>2</label>Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Korea; <email>owenmjy@jejunu.ac.kr</email> (J.Y.M.); <email>meran@jejunu.ac.kr</email> (M.K.E.)</aff>
<aff id="af3-cancers-12-00268"><label>3</label>Faculty of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Korea</aff>
<author-notes>
<corresp id="c1-cancers-12-00268"><label>*</label>Correspondence: <email>somikim@jejunu.ac.kr</email>; Tel.: +82-010-8660-1842</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>12</volume>
<issue>2</issue>
<elocation-id>268</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Resistance to chemotherapy and radiation therapy is considered a major therapeutic barrier in breast cancer. Cancer stem cells (CSCs) play a prominent role in chemo and radiotherapy resistance. The established chemo and radio-resistant triple-negative breast cancer (TNBC) cell line MDA-MB-231/IR displays greater CSC characteristics than the parental MDA-MB-231 cells. Escalating evidence demonstrates that metadherin (MTDH) is associated with a number of cancer signaling pathways as well as breast cancer therapy resistance, making it an attractive therapeutic target. Kaplan–Meier plot analysis revealed a correlation between higher levels of MTDH and shorter lifetimes in breast cancer and TNBC patients. Moreover, there was a positive correlation between the MTDH and CD44 expression levels in The Cancer Genome Atlas breast cancer database. We demonstrate that MTDH plays a pivotal role in the regulation of stemness in MDA-MB-231/IR cells. Knockdown of MTDH in MDA-MB-231/IR cells resulted in a reduction in the CSC population, aldehyde dehydrogenase activity, and major CSC markers, including β-catenin, CD44<sup>+</sup>, and Slug. In addition, MTDH knockdown increased reactive oxygen species (ROS) levels in MDA-MB-231/IR cells. We found that phenethyl isothiocyanate (PEITC), a well-known pro-oxidant phytochemical, suppressed stemness in MDA-MB-231/IR cells through ROS modulation via the downregulation of MTDH. Co-treatment of PEITC and N-Acetylcysteine (a ROS scavenger) caused alterations in PEITC induced cell death and CSC markers. Moreover, PEITC regulated MTDH expression at the post-transcriptional level, which was confirmed using cycloheximide, a protein synthesis inhibitor.</p>
</abstract>
<kwd-group>
<kwd>phenethyl isothiocyanate</kwd>
<kwd>metadherin</kwd>
<kwd>cancer stem cells</kwd>
<kwd>resistance</kwd>
<kwd>reactive oxygen species</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cancers-12-00268" sec-type="intro">
<title>1. Introduction</title>
<p>Breast cancer remains the most frequently diagnosed cancer among women. Among the breast cancer sub-types, triple negative breast cancer (TNBC) is the most aggressive, accounting for 12–18% of all breast cancer cases. As TNBC cells lack the expression of hormone receptors (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 (HER-2), TNBC tumors do not respond to hormonal therapy [<xref ref-type="bibr" rid="B1-cancers-12-00268">1</xref>]. Therefore, chemotherapy, radiotherapy, and surgery are widely used for the treatment of TNBC [<xref ref-type="bibr" rid="B2-cancers-12-00268">2</xref>]. However, resistance to chemo and radiotherapies has been identified as a major obstacle in TNBC treatment.</p>
<p>Cancer stem cells (CSCs) possess an inherited capacity to self-renew and differentiate into distinct cancer cell types and display enhanced resistance to chemo and radiotherapies, making them extremely tumorigenic. Over the past decade, breast CSCs (BCSCs) have been identified as a promising target in breast cancer therapy [<xref ref-type="bibr" rid="B2-cancers-12-00268">2</xref>,<xref ref-type="bibr" rid="B3-cancers-12-00268">3</xref>]. The CSC markers CD44<sup>+</sup>/CD24<sup>−</sup> are well-established surface bio-markers in BCSCs. CSCs are regulated through a range of key signaling pathways, such as Wnt/β-catenin, Notch, Hedgehog, phosphatase and tensin homolog (PTEN), and NF-κB, and irregularities in these signaling pathways are frequently found in CSCs [<xref ref-type="bibr" rid="B4-cancers-12-00268">4</xref>]. Elevated aldehyde dehydrogenase (ALDH) levels and overexpression of ATP-binding cassette (ABC) transporters such as multidrug resistance protein 1 (MRP1)/ABCC1, multidrug resistance 1 (MDR1), P-glycoprotein (Pgp)/ABCC1, and breast cancer resistance protein (BCRP)/ABCG2/ABCP are commonly observed in CSCs [<xref ref-type="bibr" rid="B4-cancers-12-00268">4</xref>]. Moreover, enhanced epithelial-to-mesenchymal transition (EMT) activity is recognized as a CSC marker [<xref ref-type="bibr" rid="B4-cancers-12-00268">4</xref>]. Low reactive oxygen species (ROS) levels and elevated free radical scavengers have also been identified in CSCs [<xref ref-type="bibr" rid="B5-cancers-12-00268">5</xref>], and ROS has been identified as an important target in the treatment of CSCs [<xref ref-type="bibr" rid="B6-cancers-12-00268">6</xref>,<xref ref-type="bibr" rid="B7-cancers-12-00268">7</xref>,<xref ref-type="bibr" rid="B8-cancers-12-00268">8</xref>].</p>
<p>Among the various phytochemicals with anti-cancer effects, phenethyl isothiocyanate (PEITC) is one of the most prominent phytochemicals reported to control ROS levels in cancer cells [<xref ref-type="bibr" rid="B9-cancers-12-00268">9</xref>]. Several studies have demonstrated that PEITC can exert pro-oxidant effects by depleting glutathione levels [<xref ref-type="bibr" rid="B10-cancers-12-00268">10</xref>,<xref ref-type="bibr" rid="B11-cancers-12-00268">11</xref>,<xref ref-type="bibr" rid="B12-cancers-12-00268">12</xref>]. Moreover, a number of investigations have illustrated that PEITC can effectively target cancer cells by promoting the inhibition of cell proliferation and invasiveness [<xref ref-type="bibr" rid="B13-cancers-12-00268">13</xref>,<xref ref-type="bibr" rid="B14-cancers-12-00268">14</xref>,<xref ref-type="bibr" rid="B15-cancers-12-00268">15</xref>], inducing apoptosis [<xref ref-type="bibr" rid="B16-cancers-12-00268">16</xref>,<xref ref-type="bibr" rid="B17-cancers-12-00268">17</xref>,<xref ref-type="bibr" rid="B18-cancers-12-00268">18</xref>] and cell cycle arrest [<xref ref-type="bibr" rid="B19-cancers-12-00268">19</xref>,<xref ref-type="bibr" rid="B20-cancers-12-00268">20</xref>,<xref ref-type="bibr" rid="B21-cancers-12-00268">21</xref>,<xref ref-type="bibr" rid="B22-cancers-12-00268">22</xref>] in vitro and in vivo. However, studies on the potential anti-cancer efficacy of PEITC and its mechanism in CSCs, especially BCSCs, are extremely limited.</p>
<p>Metadherin (MTDH), also known as Lysine-rich CEACAM-1-associated protein (LYRIC) [<xref ref-type="bibr" rid="B23-cancers-12-00268">23</xref>] or astrocyte elevated gene-1 (AEG) [<xref ref-type="bibr" rid="B24-cancers-12-00268">24</xref>,<xref ref-type="bibr" rid="B25-cancers-12-00268">25</xref>], is a tumor antigen mainly found in the cell membrane, cytoplasm, and nucleus [<xref ref-type="bibr" rid="B25-cancers-12-00268">25</xref>]. Overexpression of MTDH has been reported in many cancer types, including liver [<xref ref-type="bibr" rid="B26-cancers-12-00268">26</xref>,<xref ref-type="bibr" rid="B27-cancers-12-00268">27</xref>], prostate [<xref ref-type="bibr" rid="B28-cancers-12-00268">28</xref>,<xref ref-type="bibr" rid="B29-cancers-12-00268">29</xref>], colorectal [<xref ref-type="bibr" rid="B30-cancers-12-00268">30</xref>], glioblastoma [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>], and breast cancers [<xref ref-type="bibr" rid="B32-cancers-12-00268">32</xref>,<xref ref-type="bibr" rid="B33-cancers-12-00268">33</xref>]. MTDH has been reported to regulate two distinct signaling pathways implicated in tumorigenesis and metastasis: The NF-κB [<xref ref-type="bibr" rid="B34-cancers-12-00268">34</xref>,<xref ref-type="bibr" rid="B35-cancers-12-00268">35</xref>] and mitogen - activated protein kinase (MAPK) [<xref ref-type="bibr" rid="B36-cancers-12-00268">36</xref>,<xref ref-type="bibr" rid="B37-cancers-12-00268">37</xref>] pathways. Several studies have indicated that MTDH can play a crucial role in the maintenance of low ROS levels [<xref ref-type="bibr" rid="B38-cancers-12-00268">38</xref>] and CSC populations by regulating transcriptional factors such as Twist or β-catenin [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>]. In addition, elevated expression of MTDH has been associated with breast cancer therapy resistance [<xref ref-type="bibr" rid="B33-cancers-12-00268">33</xref>,<xref ref-type="bibr" rid="B39-cancers-12-00268">39</xref>]. However, information on pre-clinical investigations assessing the effects of natural compounds on MTDH expression is extremely limited. The lack of pre-clinical data on MTDH targeting by natural products and the ability of PEITC to regulate ROS levels in CSCs led us to investigate the inhibitory effects of PEITC on stemness in our established chemo and radioresistant TNBC cell line, MDA-MB-231/IR.</p>
</sec>
<sec id="sec2-cancers-12-00268" sec-type="results">
<title>2. Results</title>
<sec id="sec2dot1-cancers-12-00268">
<title>2.1. Stem Cell Characteristics of MDA-MB-231/IR Cells</title>
<p>MDA-MB-231/IR cells were established in our laboratory by irradiating MDA-MB-231 cells at a dose of 2 Gy for 25 cycles [<xref ref-type="bibr" rid="B40-cancers-12-00268">40</xref>]. In contrast to the parental cell line MDA-MB-231, MDA-MB-231/IR cells displayed mesenchymal-like morphology with a spindle-shaped appearance (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>a). They also exhibited an enriched CSC population, as evidenced by the increased mammosphere formation capacity (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>b), CD44<sup>+</sup>/CD24<sup>−</sup> population (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>c), and ALDH activity (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>d). This observation was strongly supported by Western blot analysis, which showed increased expression of CSC markers such as CD44, Oct3/4, and MRP1 (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>e). Moreover, there was a significant increase in the cell invasion capability of MDA-MB-231/IR cells compared to MDA-MB-231 cells (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>f). Correlating with this, the EMT marker Slug was overexpressed in MDA-MB-231/IR cells (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>e). These results indicate that MDA-MB-231/IR cells exhibit an enriched CSC population compared to the non-irradiated parental MDA-MB-231 cells.</p>
</sec>
<sec id="sec2dot2-cancers-12-00268">
<title>2.2. MDA-MB-231/IR Cells Exhibited Low ROS Levels</title>
<p>Numerous studies have shown that CSCs possess increased ROS scavenging activities, leading to lower ROS levels than the levels in cancer cells [<xref ref-type="bibr" rid="B5-cancers-12-00268">5</xref>]. We found that the ROS levels in MDA-MB-231/IR cells were 1.83-fold lower than in the parental cells (<xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>a). A glutathione (GSH) assay was performed to measure the GSH levels in the two cell lines, since GSH has been reported to be a major ROS scavenger [<xref ref-type="bibr" rid="B41-cancers-12-00268">41</xref>]. As shown in <xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>b, the MDA-MB-231/IR cells exhibited higher GSH levels. Correlating with these results, there was increased expression of antioxidant genes [<xref ref-type="bibr" rid="B42-cancers-12-00268">42</xref>] such as NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), glutamate-cysteine ligase modifier subunit (GCLM), thioredoxin reductase 1 (TXNRD1), sulfiredoxin 1 (SRXN1), and microsomal glutathione S-transferase 3 (MQST3) (<xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>c). These results demonstrate that, in contrast to MDA-MB-231 cells, MDA-MB-231/IR cells maintained low ROS levels due to their higher expression of ROS scavengers.</p>
</sec>
<sec id="sec2dot3-cancers-12-00268">
<title>2.3. MTDH Expression is Significantly Correlated with Poorer Prognosis in Breast Cancer Patient Samples</title>
<p>Kaplan–Meier plot analysis was performed to examine the correlation between MTDH expression and the survival rates of breast cancer and TNBC patients. Higher expressions of MTDH and shorter lifetimes were found to be correlated in breast cancer and TNBC patients, as shown in <xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>a,b, respectively. Moreover, Xena browser analysis indicated a higher expression of MTDH at the mRNA level in primary tumor samples compared to normal tissue (<xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>c) (<italic>n</italic> = 1247, <italic>p</italic>-value = 7.699 × 10<sup>−9</sup>, f = 18.97). Xena browser analysis also revealed a positive correlation between the MTDH and CD44 expression levels in The Cancer Genome Atlas (TCGA) breast cancer database (<xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>d) (<italic>n</italic> = 1247, r = 0.05725, <italic>p</italic>-value = 0.04586). The positive correlation of MTDH with poor prognosis in breast cancer patients suggests that MTDH is an ideal target for chemotherapy.</p>
</sec>
<sec id="sec2dot4-cancers-12-00268">
<title>2.4. MTDH Plays a Key Role in Maintenance of the CSC Population in MDA-MB-231/IR Cells</title>
<p>As MTDH has been reported to play a prominent role in breast cancer therapy resistance [<xref ref-type="bibr" rid="B33-cancers-12-00268">33</xref>,<xref ref-type="bibr" rid="B39-cancers-12-00268">39</xref>] and maintenance of the CSC population [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>], we examined whether MTDH could play a role in the stemness of MDA-MB-231/IR cells. We found that MTDH was overexpressed (1.44-fold) in MDA-MB-231/IR cells compared to the parental MDA-MB-231 cells (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>a). <xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>b shows that the knockdown of MTDH resulted in a decrease in the MTDH protein levels (2.43-fold reduction) compared to the si-RNA control, and inhibition of MTDH expression in MDA-MB-231/IR cells resulted in reductions in mammosphere formation (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>c) and ALDH activity (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>c,d). These results were supported by decreases in CSC markers such as β-catenin and Slug (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>b). Moreover, increased ROS production was observed (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>e), as well as reductions in both total CD44 expression (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>b) and CD44 expression on cell surfaces (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>f) following the knockdown of MTDH. These results show that MTDH is responsible for the maintenance of the CSC population in MDA-MB-231/IR cells.</p>
</sec>
<sec id="sec2dot5-cancers-12-00268">
<title>2.5. PEITC Reduced MDA-MB-231/IR Cell Viability by Inducing ROS Accumulation</title>
<p>An MTT assay was performed to compare the effects of PEITC on the proliferation of MDA-MB-231 and MDA-MB-231/IR cells. As shown in <xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>a, PEITC reduced the viability of MDA-MB-231/IR cells, with an IC<sub>50</sub> of 9.29 μM. PEITC exerted non-cytotoxic effects in MCF-10A (mammary epithelial cells) and fibroblast cells (<xref ref-type="app" rid="app1-cancers-12-00268">Figure S1</xref>). As PEITC has been reported to be a pro-oxidant substance due to its conjugation with GSH [<xref ref-type="bibr" rid="B41-cancers-12-00268">41</xref>], we measured ROS and GSH levels in MDA-MB-231/IR cells after exposure to PEITC at different time points (1.5, 3, 6, and 12 h). As seen in <xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>b, the ROS levels were increased in a dose-dependent manner at each time point tested, following a sharp enhancement in the expression of antioxidant genes (<xref ref-type="app" rid="app1-cancers-12-00268">Figure S2</xref>). Correlating with these results, GSH levels were reduced at 1.5, 3, and 6 h post incubation (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>c). N-Acetylcysteine (NAC), a ROS scavenger [<xref ref-type="bibr" rid="B43-cancers-12-00268">43</xref>], was used to examine whether the cytotoxic effects of PEITC were caused by elevated ROS production. Co-treatment with NAC and PEITC allowed for the proliferation of MDA-MB-231/IR cells, confirming that the PEITC-induced reduction of MDA-MB-231/IR cell proliferation was due to the increased ROS levels (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>d). These data demonstrate that PEITC can selectively target MDA-MB-231/IR cells by promoting ROS accumulation.</p>
</sec>
<sec id="sec2dot6-cancers-12-00268">
<title>2.6. PEITC Reduced Stemness and the Expression of MTDH and CSC Markers in MDA-MB-231/IR Cells</title>
<p>Next, we evaluated whether PEITC could suppress the CSC population of MDA-MB-231/IR cells. PEITC dramatically reduced the formation of mammospheres in MDA-MB-231/IR cells after exposure for 24 h at the doses shown in <xref ref-type="fig" rid="cancers-12-00268-f006">Figure 6</xref>a. In addition, the CD44<sup>+</sup>/CD24<sup>−</sup> population was decreased in a dose-dependent manner after PEITC treatment (<xref ref-type="fig" rid="cancers-12-00268-f006">Figure 6</xref>b). Inhibition of ALDH activity and the suppression of cell migration and invasion at non-lethal concentrations of PEITC were also apparent (<xref ref-type="fig" rid="cancers-12-00268-f006">Figure 6</xref>c–e). These observations were further supported by Western blot analysis, in which reduced expression of Slug was observed (<xref ref-type="fig" rid="cancers-12-00268-f006">Figure 6</xref>f). Next, we examined the effect of PEITC on the expression of MTDH and CSC markers. As seen in <xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>a, PEITC significantly reduced the expression of MTDH and CSC markers in a time-dependent manner. Co-treatment with NAC prevented the decrease in the expression of these proteins triggered by PEITC (<xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>b). All of these data demonstrate that PEITC effectively reduced CSCs and CSC markers in MDA-MB-231/IR cells, accompanied by decreased MTDH levels.</p>
</sec>
<sec id="sec2dot7-cancers-12-00268">
<title>2.7. PEITC Downregulated MTDH at the Post-Transcriptional Level</title>
<p>We further investigated the underlying mechanism associated with the suppression of MTDH induced by PEITC. Interestingly, there was no reduction in the <italic>MTDH</italic> mRNA levels, but the levels of the MTDH protein were dramatically reduced after treatment with 10 μM PEITC for 24 h (<xref ref-type="fig" rid="cancers-12-00268-f008">Figure 8</xref>a,b). Based on these results, we hypothesized that PEITC could regulate MTDH at the post-transcriptional level. To confirm this, the MTDH levels were measured by Western blotting after cells were treated with cycloheximide, a ribosome inhibitor [<xref ref-type="bibr" rid="B44-cancers-12-00268">44</xref>], with or without PEITC. As shown in <xref ref-type="fig" rid="cancers-12-00268-f008">Figure 8</xref>c, compared to cells treated with cycloheximide alone, cells treated with both cycloheximide and PEITC exhibited a dramatic reduction in the expression of MTDH after incubation for 120 min, indicating that the expression of MTDH is regulated at the post-transcriptional level.</p>
</sec>
</sec>
<sec id="sec3-cancers-12-00268" sec-type="discussion">
<title>3. Discussion</title>
<p>CSCs play a major role in chemo and radio-resistance in breast cancer patients [<xref ref-type="bibr" rid="B45-cancers-12-00268">45</xref>]. In a recent study, we generated a chemo and radio-resistant MDA-MB-231/IR cell line that exhibited enhanced CSC characteristics in comparison to its parental cell line MDA-MB-231 [<xref ref-type="bibr" rid="B40-cancers-12-00268">40</xref>]. However, the underlying mechanisms responsible for this phenomenon are still unclear. In this study, we showed that MDA-MB-231/IR cells have typical stem cell characteristics such as increased mammosphere formation capacity, increased CD44<sup>+</sup>/CD24<sup>−</sup> populations, enhanced expression of CSC markers such as CD44, Oct3/4, Slug, and MRP1, and enhanced invasion capability (<xref ref-type="fig" rid="cancers-12-00268-f001">Figure 1</xref>b–f). In addition, we examined ALDH activity since ALDH has widely been used as a CSC marker in BCSCs [<xref ref-type="bibr" rid="B4-cancers-12-00268">4</xref>]. We found that MDA-MB-231/IR cells exhibited higher ALDH activity than MDA-MB-231 cells, thereby reaffirming the stemness of the MDA-MB-231/IR cells. Furthermore, as lower ROS levels have been recognized as a hallmark feature of CSCs, and ROS are crucial mediators of radiation-induced cell death [<xref ref-type="bibr" rid="B5-cancers-12-00268">5</xref>], we tested whether MDA-MB-231/IR cells accumulated lower ROS levels than MDA-MB-231 cells. Our results showed that the ROS levels were reduced in MDA-MB-231/IR cells, and this was associated with higher expressions of ROS scavengers such as GSH [<xref ref-type="bibr" rid="B43-cancers-12-00268">43</xref>] (<xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>b) and antioxidant genes (<xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>c). These results suggest that ROS are ideal targets for CSC-targeted therapies [<xref ref-type="bibr" rid="B6-cancers-12-00268">6</xref>,<xref ref-type="bibr" rid="B7-cancers-12-00268">7</xref>,<xref ref-type="bibr" rid="B8-cancers-12-00268">8</xref>].</p>
<p>We further identified the underlying mechanisms associated with the enrichment of the CSC population in MDA-MB-231/IR cells. It has been reported that MTDH plays a key role in cancer therapy resistance due to its ability to maintain CSC populations [<xref ref-type="bibr" rid="B14-cancers-12-00268">14</xref>,<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>,<xref ref-type="bibr" rid="B35-cancers-12-00268">35</xref>]. Elevated expressions of MTDH are associated with poor prognoses in breast cancer and TNBC patients (<xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>a,b). Additionally, MTDH has been found to be more highly expressed in primary tumor tissues than in normal tissues (<xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>c). Moreover, previous studies have shown that MTDH can regulate the NF-κB pathway [<xref ref-type="bibr" rid="B34-cancers-12-00268">34</xref>,<xref ref-type="bibr" rid="B35-cancers-12-00268">35</xref>] and MTDH is induced by the TNF-α pathway [<xref ref-type="bibr" rid="B46-cancers-12-00268">46</xref>]. Our previous study revealed that MDA-MB-231/IR cells show enhanced activity in the NF-κB pathway, the TNF signaling pathway, and the Toll-like receptor pathway [<xref ref-type="bibr" rid="B40-cancers-12-00268">40</xref>]. Xena browser analysis revealed a positive correlation between MTDH and the BCSC marker CD44 in breast cancer patients (<xref ref-type="fig" rid="cancers-12-00268-f003">Figure 3</xref>d). In light of these findings, we hypothesized that MTDH plays a critical role in the stemness of MDA-MB-231/IR cells. Western blot analysis revealed an increase in MTDH expression in MDA-MB-231/IR cells (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>a). Then, to confirm the role of MTDH in maintaining the CSC population in this line, MTDH was knocked down using si-MTDH. Successful knockdown of MTDH (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>b) resulted in a reduction in the CSC population, as evidenced by reduced mammosphere formation capacity (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>c) and ALDH activity (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>d). Western blot results (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>b) showing decreased levels of CSC markers, such as β-catenin, CD44, and Slug, strongly support our data. The CD44-positive population was also reduced after knockdown of MTDH (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>f). Numerous studies have reported that MTDH can promote CSC characteristics in colorectal cancer [<xref ref-type="bibr" rid="B47-cancers-12-00268">47</xref>], glioblastoma cancer [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>], pancreatic cancer [<xref ref-type="bibr" rid="B48-cancers-12-00268">48</xref>], and breast cancer [<xref ref-type="bibr" rid="B49-cancers-12-00268">49</xref>,<xref ref-type="bibr" rid="B50-cancers-12-00268">50</xref>,<xref ref-type="bibr" rid="B51-cancers-12-00268">51</xref>]. Moreover, Hu et al. (2017) revealed that MTDH contributes to the maintenance of glioblastoma CSCs by protecting β-catenin from phosphorylation and degradation by proteasomes. In addition, β-catenin translocates into the nucleus and acts as a transcription factor to activate CSC-related downstream genes [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>]. Knockdown of MTDH also resulted in enhanced ROS levels (<xref ref-type="fig" rid="cancers-12-00268-f004">Figure 4</xref>e). It has been reported that MTDH knockdown can induce ROS production, and MTDH overexpression has resulted in reduced ROS levels [<xref ref-type="bibr" rid="B38-cancers-12-00268">38</xref>].</p>
<p>It is well-established that PEITC promotes ROS accumulation by covalently binding to GSH [<xref ref-type="bibr" rid="B41-cancers-12-00268">41</xref>,<xref ref-type="bibr" rid="B52-cancers-12-00268">52</xref>]. Since MDA-MB-231/IR cells exhibited increased ROS scavenger machinery, including GSH and antioxidant genes, resulting in very low ROS levels (<xref ref-type="fig" rid="cancers-12-00268-f002">Figure 2</xref>a), we hypothesized that by inducing ROS accumulation, PEITC could target the CSC population in MDA-MB-231/IR cells. Our results showed that PEITC could eliminate the CSC population in MDA-MB-231/IR cells, as evidenced by the significant inhibition of mammosphere formation, the CD44<sup>+</sup>/CD24<sup>−</sup> population, and ALDH activity (<xref ref-type="fig" rid="cancers-12-00268-f006">Figure 6</xref>a–c). PEITC has been reported to target CSC compartments in a variety of cancers, including cervical cancer [<xref ref-type="bibr" rid="B53-cancers-12-00268">53</xref>], colon cancer [<xref ref-type="bibr" rid="B33-cancers-12-00268">33</xref>], colorectal cancer [<xref ref-type="bibr" rid="B54-cancers-12-00268">54</xref>], and HeLa cancer cells [<xref ref-type="bibr" rid="B10-cancers-12-00268">10</xref>]. Recently, Koschorke et al. (2019) found that PEITC can target HER-2 positive BCSCs, and this effect was enhanced in combination with trastuzumab therapy [<xref ref-type="bibr" rid="B55-cancers-12-00268">55</xref>]. Moreover, Western blot analysis revealed that PEITC can reduce levels of CD44, Oct3/4, and MRP-1, which are widely used as BCSC markers (<xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>a). In addition, the levels of β-catenin, a transcription factor that contributes to the expression of many CSC genes [<xref ref-type="bibr" rid="B31-cancers-12-00268">31</xref>], were significantly reduced after incubation with PEITC (<xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>a). Chen et al. (2018) reported that PEITC significantly inhibits sphere formation in colorectal cancer by targeting the Wnt/β-catenin pathway [<xref ref-type="bibr" rid="B54-cancers-12-00268">54</xref>]. Importantly, incubation with PEITC promoted ROS production (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>b) and decreased GSH levels (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>c). However, during longer incubations with PEITC, decreased ROS levels were detected (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>b). This can be explained by the complicated activities of ROS scavengers inside the cells. In addition to GSH, antioxidant genes can also control ROS levels. The rapidly elevated ROS levels after PEITC treatments of just 1.5, 3, and 6 h activated the expression of antioxidant genes (<xref ref-type="app" rid="app1-cancers-12-00268">Figure S2</xref>). We then used NAC, a known ROS scavenger [<xref ref-type="bibr" rid="B43-cancers-12-00268">43</xref>], to confirm our hypothesis. Co-treatment with PEITC and NAC prevented the changes in cell death (<xref ref-type="fig" rid="cancers-12-00268-f005">Figure 5</xref>d) and CSC markers (<xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>b) that are induced by PEITC. Indeed, through enhanced ROS accumulation, PEITC could erase the CSC characteristics induced by irradiation in MDA-MB-231 cells.</p>
<p>Ours is the first report to show that PEITC can target MTDH at the post-transcriptional level in radiation-induced CSCs of TNBC cells. We found that, while there was no significant change in MTDH expression at the mRNA level, the levels of MTDH protein were dramatically reduced after 24 h of exposure to 10 μM PEITC (<xref ref-type="fig" rid="cancers-12-00268-f008">Figure 8</xref>a,b). Moreover, co-treatment with cycloheximide, a ribosome inhibitor [<xref ref-type="bibr" rid="B44-cancers-12-00268">44</xref>], dramatically reduced MTDH expression in MDA-MB-231/IR cells after incubation for 120 min (<xref ref-type="fig" rid="cancers-12-00268-f008">Figure 8</xref>c). These data strongly suggest that PEITC regulates MTDH at the post-transcriptional level. One of the best-known mechanisms supporting this phenomenon is the ubiquitin-proteasome proteolytic pathway. Once a protein is conjugated with a poly-ubiquitin chain, it is recognized and degraded by the proteasome system [<xref ref-type="bibr" rid="B56-cancers-12-00268">56</xref>]. PEITC has been reported to induce ubiquitination through the inhibition of deubiquitinase activity [<xref ref-type="bibr" rid="B57-cancers-12-00268">57</xref>]. MicroRNAs may also play a role in the regulation of MTDH expression by PEITC. MicroRNAs are groups of small RNAs (−22 nucleotides in length) that function by binding to complementary target sequences of messenger RNAs. [<xref ref-type="bibr" rid="B58-cancers-12-00268">58</xref>]. The TargetScan Human analysis software (<xref ref-type="app" rid="app1-cancers-12-00268">Figure S3</xref>) revealed that MTDH is regulated by several microRNAs [<xref ref-type="bibr" rid="B59-cancers-12-00268">59</xref>]. The microRNAs miR-26, miR-142, and miRNA-135 have been identified as possible targets of PEITC [<xref ref-type="bibr" rid="B60-cancers-12-00268">60</xref>]. These findings provide a strong rationale to further investigate the mechanistic roles of the ubiquitin-proteasome proteolytic pathway as well as the PEITC-targeted miRNAs in the post-transcriptional regulation of MTDH by PEITC. In-depth follow-up studies are needed to determine the specific mechanisms that regulate the expression of MTDH. In summary, our study demonstrates, for the first time, that PEITC can target MTDH in MTDH-overexpressing radioresistant MDA-MB-231/IR cells by increasing ROS production.</p>
<p>It is has reported that PEITC can exert anti-metastatic effects in a breast cancer cell model [<xref ref-type="bibr" rid="B61-cancers-12-00268">61</xref>]. Moreover, PEITC has enhanced the efficacy of chemotherapy drugs such as doxorubicin and paclitacxel in breast cancer cells [<xref ref-type="bibr" rid="B61-cancers-12-00268">61</xref>]. Moreover, PEITC treatment has been reported to inhibit breast tumor growth via suppressing T regulatory lymphocytes [<xref ref-type="bibr" rid="B61-cancers-12-00268">61</xref>]. In a recent publication, PEITC has been shown to inhibit the activity of proteasomal cysteine deubiquitinases UCHL5 [<xref ref-type="bibr" rid="B62-cancers-12-00268">62</xref>]. Through depleting GSH levels, PEITC sensitized breast cancer cells to radiation by modulating cellular metabolism [<xref ref-type="bibr" rid="B63-cancers-12-00268">63</xref>]. Growing evidence of in-vitro therapeutic efficacy of cruciferous vegetables derived isothiocyanates or extracts has provided a strong rational to investigate their therapeutic potential in several clinical studies. Among isothiocyanates, phenethyl isothiocyanate and sulforaphane have provided promising results in some cancer and autism clinical trials. Apart from cancer and autism, cruciferous vegetables derived isothiocyanates or extracts have been clinically investigated for skin disorders, diabetes, heart diseases, and respiratory conditions [<xref ref-type="bibr" rid="B64-cancers-12-00268">64</xref>]. Clinical trials of cruciferous vegetables derived isothiocyanates are extremely limited in breast cancer. A study conducted by Atwell el al. in 2015 showed that glucoraphanin, a well-known broccoli glucosinolate, can mediate epigenetics alterations in peripheral blood mononuclear cells without producing significant alterations in breast cancer tissue tumor biomarkers [<xref ref-type="bibr" rid="B65-cancers-12-00268">65</xref>]. New findings of the present investigation in radiotherapy resistant triple negative breast cancer cells will provide a rational basis for conducting future clinical investigations with phenethyl isothiocyanate in breast cancer patients.</p>
</sec>
<sec id="sec4-cancers-12-00268">
<title>4. Materials and Methods</title>
<sec id="sec4dot1-cancers-12-00268">
<title>4.1. Cell Culture</title>
<p>Human TNBC cells (MDA-MB-231) and normal mammary epithelial cells (MCF-10A) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). The radioresistant MDA-MB-231/IR cell line was established and characterized as previously described [<xref ref-type="bibr" rid="B40-cancers-12-00268">40</xref>]. Normal fibroblast cells were a gift from Prof. Moonjae Cho. MDA-MB-231 and MDA-MB-231/IR cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-activated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. MCF-10A cells were cultured under the ATCC-recommended culture conditions. All cells were maintained at 37 °C with a 5% CO<sub>2</sub> atmosphere.</p>
</sec>
<sec id="sec4dot2-cancers-12-00268">
<title>4.2. Cell Viability Assay</title>
<p>Cells (2 × 10<sup>4</sup>/mL) were seeded in 96-well plates for 24 h and treated with PEITC (Sigma, St. Louis, MO, USA). Following 24 h of incubation, 100 µL of MTT (0.5 mg/mL) dissolved in fresh medium was added to each well, and the plates were re-incubated for 2–3 h. To dissolve the formazan crystals, the medium was aspirated and 150 µL of dimethyl sulfoxide (DMSO) was added to each well. A microplate reader (Tecan Group, Ltd., Salzburg, Austria) was used to record the absorbance at 570 nm. The percentage of cell viability was calculated using the formula (control group − treated group) ÷ control group) × 100%.</p>
</sec>
<sec id="sec4dot3-cancers-12-00268">
<title>4.3. Cell Migration Assay</title>
<p>For the cell migration assay, 6-well cell culture plates were used. Initially, 1 × 10<sup>5</sup> cells were seeded and incubated for 24 h. Upon 90% confluency, scratches were manually made using a sterile pipette tip. The cells were then washed with phosphate-buffered saline (PBS) to remove detached cells and incubated with or without PEITC (0, 5 μM). Wound areas were photographed with the help of an inverted phase-contrast microscope at 4× magnification.</p>
</sec>
<sec id="sec4dot4-cancers-12-00268">
<title>4.4. Cell Invasion Assay</title>
<p>A Transwell system (24-well plate; Corning, Cambridge, MA, USA) was used to examine cell invasion. In the upper chamber, matrigel was coated and cells (1.5 × 10<sup>5</sup> per Transwell) were seeded in 200 µL of serum-free medium, supplemented with or free of, PEITC. The lower chamber was filled with 750 µL of DMEM supplemented with 10% FBS. Following 24 h of incubation, invading cells were fixed with 4% paraformaldehyde followed by methanol. Finally, the cells were stained with 2% crystal violet and were observed under a phase-contrast microscope.</p>
</sec>
<sec id="sec4dot5-cancers-12-00268">
<title>4.5. Flow Cytometric Analysis of the CD44<sup>+</sup>/CD24<sup>−</sup> Population</title>
<p>Fluorescence-activated cell sorting (FACS) was conducted to analyze the expression of the CD44 and CD24 markers. Briefly, 1 × 10<sup>6</sup> cells were suspended in 100 μL of immunofluorescence staining buffer supplemented with PE-conjugated anti-human CD24 antibody (BD Pharmingen, San Diego, CA, USA) and FITC-conjugated anti-human CD44 antibody (BD Pharmingen) and incubated for 10 min at 4 °C. Following incubation, the cells were washed with PBS and the CD44<sup>+</sup>/CD24<sup>−</sup> cell population was determined using a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).</p>
</sec>
<sec id="sec4dot6-cancers-12-00268">
<title>4.6. Aldefluor Assay</title>
<p>The ALDEFLUOR assay kit (Stemcell Technologies, Vancouver, BC, Canada) was used to measure ALDH enzyme activity. Diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH, was used as the negative control. Prior to the assay, 3 × 10<sup>4</sup> cells/mL were cultured in 60 mm dishes and incubated for 24 h. Following incubation, the cells were exposed to PEITC (5 μM, non-toxic concentration) for 24 h, and then the ALDEFLUOR assay was performed. The samples were analyzed for ALDH-positive cells using a FACSCalibur flow cytometer.</p>
</sec>
<sec id="sec4dot7-cancers-12-00268">
<title>4.7. Mammosphere Formation Assay</title>
<p>For the mammosphere formation assay, 2 × 10<sup>4</sup> cells/mL were seeded as single cells in ultralow-attachment dishes containing complete MammoCult Human Medium (Stemcell Technologies) supplemented with or without PEITC (0, 5, 10, 15, or 20 μM). After 7 days of incubation, mammospheres were observed (larger than 60 μm) under a phase-contrast microscope.</p>
</sec>
<sec id="sec4dot8-cancers-12-00268">
<title>4.8. Real-Time PCR</title>
<p>Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Following reverse transcription, two-step quantitative real-time PCR was performed (Takara, Shiga, Japan). The primers used for real-time PCR experiments are listed in <xref ref-type="app" rid="app1-cancers-12-00268">Table S1</xref>. GAPDH, a housekeeping gene was used as an internal control. The results are expressed using the formula 2−ΔΔCq [<xref ref-type="bibr" rid="B66-cancers-12-00268">66</xref>].</p>
</sec>
<sec id="sec4dot9-cancers-12-00268">
<title>4.9. Western Blot Analysis</title>
<p>Western blot analysis was conducted, as previously described [<xref ref-type="bibr" rid="B67-cancers-12-00268">67</xref>]. Briefly, cell lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer and quantified using a commercially available kit. After determining the protein concentrations, 20–40 µg of proteins were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis and were electrophoretically transferred to PVDF membrane. After blocking with skim milk, the membranes were exposed to different primary antibodies. Except for the anti-GAPDH primary antibody (1:7000 dilution), the primary antibodies were diluted 1:1000. All primary antibodies were purchased from the Cell Signaling Technology (Beverly, MA, USA). The anti-rabbit immunoglobulin G (IgG) secondary antibody (Vector Laboratories, Burlingame, CA, USA) was diluted 1:5000 prior to use. Bands were detected using the BS ECL Plus Kit (Biosesang, Seongnam, South Korea). ImageJ software (US National Institutes of Health, Bethesda, MD, USA) was used to quantify bands.</p>
</sec>
<sec id="sec4dot10-cancers-12-00268">
<title>4.10. siRNA Knockdown</title>
<p>To knock down MTDH, a small interfering RNA specific for MTDH (si-MTDH) and a scrambled siRNA control (si-Control) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Cells were seeded at 5 × 10<sup>4</sup> cells/well in 6-well plates and incubated for 24 h. Then, the cells were transfected for 48 h with si-MTDH using the Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s instructions. The protein expression levels after MTDH knockdown were determined by Western blotting.</p>
</sec>
<sec id="sec4dot11-cancers-12-00268">
<title>4.11. ROS Generation Analysis</title>
<p>Prior to the assay, 3 × 10<sup>6</sup> cells/mL were seeded in 60 mm culture dishes. After 24 h of incubation, the cells were treated with or without PEITC and re-incubated for 1.5, 3, 6, or 12 h. To analyze ROS generation, the cells were stained with 2′,7′-dichlorofluorescin diacetate (H<sub>2</sub>DCFDA) for 15 min, followed by washing with 2 mL of PBS. A FACSCalibur flow cytometer was used to assess the ROS levels.</p>
</sec>
<sec id="sec4dot12-cancers-12-00268">
<title>4.12. GSH Assay</title>
<p>GSH activity was measured using a GSH assay kit (Cayman Chemical, Ann Arbor, MI, USA). Cells (3 × 10<sup>6</sup> cells/mL) were cultured in 60 mm culture dishes and incubated for 24 h. After incubation, the cells were exposed to different concentrations of PEITC (0, 5, 10, 15, or 20 μM) for 1.5, 3, 6, or 12 h. GSH activity was measured according to the manufacturer’s instructions.</p>
</sec>
<sec id="sec4dot13-cancers-12-00268">
<title>4.13. Correlation Analysis by the Kaplan–Meier Plotter</title>
<p>The Kaplan–Meier Plotter database was used to examine the correlation between the expression of MTDH and the survival of rate of breast cancer patients. The UCSC Xena browser was used to examine possible associations in the expression of MTDH and CD44 in breast cancer patient samples based on the data available in the TCGA database.</p>
</sec>
<sec id="sec4dot14-cancers-12-00268">
<title>4.14. Statistical Analysis</title>
<p>Data are presented as the mean ± standard deviation of at least three individual experiments. The data were statistically analyzed using the Student’s <italic>t</italic>-test with GraphPad software (La Jolla, CA, USA). A <italic>p</italic>-value &lt; 0.05 was considered to indicate statistical significance.</p>
</sec>
</sec>
<sec id="sec5-cancers-12-00268" sec-type="conclusions">
<title>5. Conclusions</title>
<p>In conclusion, we show here, for the first time, that MTDH plays a significant role in the regulation of stemness characteristics in radiation-induced MDA-MB-231/IR cells. PEITC is a well-known phytochemical that has been reported to elevate ROS in pre-clinical studies. In the present study, we demonstrated that PEITC can reduce the CSC population in MDA-MB-231/IR cells by upregulating the ROS levels. Furthermore, we determined that PEITC targets MTDH at the post-transcriptional level.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-cancers-12-00268">
<title>Supplementary Materials</title>
<p>The following are available online at <uri xlink:href="https://www.mdpi.com/2072-6694/12/2/268/s1">https://www.mdpi.com/2072-6694/12/2/268/s1</uri>. Table S1. Primer sequences of MTDH and anti-oxidant genes. Figure S1: MTT assay in the normal cell line MCF-10A and fibroblasts after PEITC treatment for 24 h. Figure S2: Real-time PCR analysis of antioxidant genes in MDA-MB-231/IR cells following PEITC treatment (10 µM for 1.5, 3, 6, 12, 24, or 48 h). Figure S3: Target genes of MTDH assessed by TargetScan Human analysis.</p>
<supplementary-material content-type="local-data" id="cancers-12-00268-s001">
<media xlink:href="cancers-12-00268-s001.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</app>
</app-group>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, Y.T.-K.N., J.Y.M., M.K.E. and S.K.C.; methodology, Y.T.-K.N., J.Y.M., M.K.E.; software, Y.T.-K.N., J.Y.M., M.K.E.; validation, S.K.C.; formal analysis, Y.T.-K.N., J.Y.M., M.K.E. and S.K.C.; investigation, Y.T.-K.N. and S.K.C.; resources, Y.T.-K.N., J.Y.M., and S.K.C.; data curation, Y.T.-K.N., J.Y.M., and S.K.C.; writing—Original draft preparation, Y.T.-K.N., J.Y.M., and M.K.E.; writing—Review and editing, S.K.C.; visualization, S.K.C.; supervision, S.K.C.; project administration, S.K.C.; funding acquisition, S.K.C. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded the Ministry of Education (2016R1A6A1A03012862) and by the Ministry of Science, ICT &amp; Future Planning (2016R1A2B4016005).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-cancers-12-00268">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foulkes</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Reis-Filho</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Triple-negative breast cancer</article-title>
<source/>N. Engl. J. Med.
          <year>2010</year>
<volume>363</volume>
<fpage>1938</fpage>
<lpage>1948</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1001389</pub-id>
<pub-id pub-id-type="pmid">21067385</pub-id>
</element-citation>
</ref>
<ref id="B2-cancers-12-00268">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langlands</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Horgan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dodwell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Breast cancer subtypes: Response to radiotherapy and potential radiosensitisation</article-title>
<source/>Br. J. Radiol.
          <year>2013</year>
<volume>86</volume>
<fpage>20120601</fpage>
<pub-id pub-id-type="doi">10.1259/bjr.20120601</pub-id>
<pub-id pub-id-type="pmid">23392193</pub-id>
</element-citation>
</ref>
<ref id="B3-cancers-12-00268">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yadav</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Radio resistance in breast cancer cells is mediated through TGF-β signalling, hybrid epithelial-mesenchymal phenotype and cancer stem cells</article-title>
<source/>Biomed. Pharmacother.
          <year>2019</year>
<volume>111</volume>
<fpage>119</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.055</pub-id>
<pub-id pub-id-type="pmid">30579251</pub-id>
</element-citation>
</ref>
<ref id="B4-cancers-12-00268">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gunasekaran</surname>
<given-names>V.P.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>T.V.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kundu</surname>
<given-names>G.C.</given-names>
</name>
</person-group>
<article-title>Breast cancer stem cells: Biology and therapeutic implications</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2019</year>
<volume>107</volume>
<fpage>38</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2018.12.001</pub-id>
<pub-id pub-id-type="pmid">30529656</pub-id>
</element-citation>
</ref>
<ref id="B5-cancers-12-00268">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diehn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Kalisky</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dorie</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Kulp</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Ailles</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Association of reactive oxygen species levels and radioresistance in cancer stem cells</article-title>
<source/>Nature
          <year>2009</year>
<volume>458</volume>
<fpage>780</fpage>
<pub-id pub-id-type="doi">10.1038/nature07733</pub-id>
<pub-id pub-id-type="pmid">19194462</pub-id>
</element-citation>
</ref>
<ref id="B6-cancers-12-00268">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Dihydrotanshinone-Induced NOX5 Activation Inhibits Breast Cancer Stem Cell through the ROS/Stat3 Signaling Pathway</article-title>
<source/>Oxid. Med. Cell Longev.
          <year>2019</year>
<volume>2019</volume>
<fpage>9296439</fpage>
<pub-id pub-id-type="doi">10.1155/2019/9296439</pub-id>
<pub-id pub-id-type="pmid">31019654</pub-id>
</element-citation>
</ref>
<ref id="B7-cancers-12-00268">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Jiagge</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Buschhaus</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fath</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gheordunescu</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling</article-title>
<source/>Cell Metab.
          <year>2018</year>
<volume>28</volume>
<fpage>69</fpage>
<lpage>86.e6</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2018.06.006</pub-id>
<pub-id pub-id-type="pmid">29972798</pub-id>
</element-citation>
</ref>
<ref id="B8-cancers-12-00268">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laws</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eskandari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suntharalingam</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>A reactive oxygen species-generating, cyclooxygenase-2 inhibiting, cancer stem cell-potent tetranuclear copper(ii) cluster</article-title>
<source/>Dalton Trans.
          <year>2017</year>
<volume>46</volume>
<fpage>12785</fpage>
<lpage>12789</lpage>
<pub-id pub-id-type="doi">10.1039/C7DT02789C</pub-id>
<pub-id pub-id-type="pmid">28932846</pub-id>
</element-citation>
</ref>
<ref id="B9-cancers-12-00268">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>NavaneethaKrishnan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosales</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.Y.</given-names>
</name>
</person-group>
<article-title>ROS-Mediated Cancer Cell Killing through Dietary Phytochemicals</article-title>
<source/>Oxid. Med. Cell Longev.
          <year>2019</year>
<volume>2019</volume>
<fpage>9051542</fpage>
<pub-id pub-id-type="doi">10.1155/2019/9051542</pub-id>
<pub-id pub-id-type="pmid">31217841</pub-id>
</element-citation>
</ref>
<ref id="B10-cancers-12-00268">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>1027</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20051027</pub-id>
</element-citation>
</ref>
<ref id="B11-cancers-12-00268">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nagaprashantha</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Horne</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment</article-title>
<source/>Cancer Lett.
          <year>2018</year>
<volume>413</volume>
<fpage>122</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2017.11.002</pub-id>
<pub-id pub-id-type="pmid">29113871</pub-id>
</element-citation>
</ref>
<ref id="B12-cancers-12-00268">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Targeting ROS: Selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound</article-title>
<source/>Cancer Biol.
          <year>2007</year>
<volume>6</volume>
<fpage>646</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.6.5.4092</pub-id>
<pub-id pub-id-type="pmid">17387274</pub-id>
</element-citation>
</ref>
<ref id="B13-cancers-12-00268">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models</article-title>
<source/>BMC Med.
          <year>2012</year>
<volume>10</volume>
<elocation-id>80</elocation-id>
<pub-id pub-id-type="doi">10.1186/1741-7015-10-80</pub-id>
<pub-id pub-id-type="pmid">22824293</pub-id>
</element-citation>
</ref>
<ref id="B14-cancers-12-00268">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moon</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Brazeau</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells</article-title>
<source/>Evid. Based Complement. Altern. Med.
          <year>2011</year>
<volume>2011</volume>
<pub-id pub-id-type="doi">10.1155/2011/462525</pub-id>
<pub-id pub-id-type="pmid">20953429</pub-id>
</element-citation>
</ref>
<ref id="B15-cancers-12-00268">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.Y.</given-names>
</name>
</person-group>
<article-title>Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36</article-title>
<source/>J. Cell Mol. Med.
          <year>2010</year>
<volume>14</volume>
<fpage>1485</fpage>
<lpage>1493</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00877.x</pub-id>
<pub-id pub-id-type="pmid">19840189</pub-id>
</element-citation>
</ref>
<ref id="B16-cancers-12-00268">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Harnod</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.G.</given-names>
</name>
</person-group>
<article-title>PEITC induces apoptosis of Human Brain Glioblastoma GBM8401 Cells through the extrinsic- and intrinsic-signaling pathways</article-title>
<source/>Neurochem. Int.
          <year>2015</year>
<volume>81</volume>
<fpage>32</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2015.01.001</pub-id>
<pub-id pub-id-type="pmid">25582659</pub-id>
</element-citation>
</ref>
<ref id="B17-cancers-12-00268">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Hsia</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells</article-title>
<source/>Anticancer Res.
          <year>2011</year>
<volume>31</volume>
<fpage>1691</fpage>
<lpage>1702</lpage>
<pub-id pub-id-type="pmid">21617228</pub-id>
</element-citation>
</ref>
<ref id="B18-cancers-12-00268">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukherjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis</article-title>
<source/>J. Environ. Pathol. Toxicol. Oncol.
          <year>2009</year>
<volume>28</volume>
<fpage>269</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.v28.i4.30</pub-id>
<pub-id pub-id-type="pmid">20102325</pub-id>
</element-citation>
</ref>
<ref id="B19-cancers-12-00268">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyanapalli</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fuentes</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Pung</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells</article-title>
<source/>Pharm. Res.
          <year>2016</year>
<volume>114</volume>
<fpage>175</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2016.10.021</pub-id>
</element-citation>
</ref>
<ref id="B20-cancers-12-00268">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P.Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.G.</given-names>
</name>
</person-group>
<article-title>Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G(0)/G(1) Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death</article-title>
<source/>Evid. Based Complement. Altern. Med.
          <year>2012</year>
<volume>2012</volume>
<fpage>718320</fpage>
<pub-id pub-id-type="doi">10.1155/2012/718320</pub-id>
</element-citation>
</ref>
<ref id="B21-cancers-12-00268">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khor</surname>
<given-names>T.O.</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Prawan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC)</article-title>
<source/>Mol. Carcinog.
          <year>2008</year>
<volume>47</volume>
<fpage>321</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1002/mc.20390</pub-id>
<pub-id pub-id-type="pmid">17932952</pub-id>
</element-citation>
</ref>
<ref id="B22-cancers-12-00268">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Khor</surname>
<given-names>T.O.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>PEITC induces G1 cell cycle arrest on HT-29 cells through the activation of p38 MAPK signaling pathway</article-title>
<source/>AAPS J.
          <year>2008</year>
<volume>10</volume>
<fpage>277</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1208/s12248-008-9032-9</pub-id>
<pub-id pub-id-type="pmid">18473178</pub-id>
</element-citation>
</ref>
<ref id="B23-cancers-12-00268">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutherland</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Briers</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lamond</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Bickmore</surname>
<given-names>W.A.</given-names>
</name>
</person-group>
<article-title>3D3/lyric: A novel transmembrane protein of the endoplasmic reticulum and nuclear envelope, which is also present in the nucleolus</article-title>
<source/>Exp. Cell Res.
          <year>2004</year>
<volume>294</volume>
<fpage>94</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2003.11.020</pub-id>
<pub-id pub-id-type="pmid">14980505</pub-id>
</element-citation>
</ref>
<ref id="B24-cancers-12-00268">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.Z.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Emdad</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Volsky</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1</article-title>
<source/>Gene
          <year>2005</year>
<volume>353</volume>
<fpage>8</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2005.04.006</pub-id>
<pub-id pub-id-type="pmid">15927426</pub-id>
</element-citation>
</ref>
<ref id="B25-cancers-12-00268">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thirkettle</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Girling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Sahadevan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Whitaker</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Neal</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals</article-title>
<source/>Clin. Cancer Res.
          <year>2009</year>
<volume>15</volume>
<fpage>3003</fpage>
<lpage>3013</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2046</pub-id>
<pub-id pub-id-type="pmid">19383828</pub-id>
</element-citation>
</ref>
<ref id="B26-cancers-12-00268">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-beta-catenin signaling pathway</article-title>
<source/>Carcinogenesis
          <year>2019</year>
<pub-id pub-id-type="doi">10.1093/carcin/bgz065</pub-id>
<pub-id pub-id-type="pmid">31498866</pub-id>
</element-citation>
</ref>
<ref id="B27-cancers-12-00268">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-Content Functional Screening of AEG-1 and AKR1C2 for the Promotion of Metastasis in Liver Cancer</article-title>
<source/>J. Biomol. Screen
          <year>2016</year>
<volume>21</volume>
<fpage>101</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1177/1087057115603310</pub-id>
<pub-id pub-id-type="pmid">26318406</pub-id>
</element-citation>
</ref>
<ref id="B28-cancers-12-00268">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kolibaba</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation</article-title>
<source/>Saudi J. Biol. Sci.
          <year>2018</year>
<volume>25</volume>
<fpage>975</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="doi">10.1016/j.sjbs.2018.04.015</pub-id>
<pub-id pub-id-type="pmid">30108450</pub-id>
</element-citation>
</ref>
<ref id="B29-cancers-12-00268">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kikuno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Urakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Place</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Pookot</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Majid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Igawa</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity</article-title>
<source/>Oncogene
          <year>2007</year>
<volume>26</volume>
<fpage>7647</fpage>
<lpage>7655</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1210572</pub-id>
<pub-id pub-id-type="pmid">17563745</pub-id>
</element-citation>
</ref>
<ref id="B30-cancers-12-00268">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>M.X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer</article-title>
<source/>Oncol. Rep.
          <year>2018</year>
<volume>40</volume>
<fpage>2215</fpage>
<lpage>2223</lpage>
<pub-id pub-id-type="doi">10.3892/or.2018.6581</pub-id>
<pub-id pub-id-type="pmid">30015962</pub-id>
</element-citation>
</ref>
<ref id="B31-cancers-12-00268">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Emdad</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kegelman</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.N.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Astrocyte Elevated Gene-1 Regulates beta-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal</article-title>
<source/>Mol. Cancer Res.
          <year>2017</year>
<volume>15</volume>
<fpage>225</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0239</pub-id>
<pub-id pub-id-type="pmid">27903708</pub-id>
</element-citation>
</ref>
<ref id="B32-cancers-12-00268">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Mechanisms of AEG-1 and CXCR4 gene expression regulating the epithelial-mesenchymal transition pathway involved in brain metastases of breast cancer</article-title>
<source/>J. BUON
          <year>2017</year>
<volume>22</volume>
<fpage>953</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="pmid">28952213</pub-id>
</element-citation>
</ref>
<ref id="B33-cancers-12-00268">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro</article-title>
<source/>Breast Cancer Res.
          <year>2018</year>
<volume>20</volume>
<fpage>113</fpage>
<pub-id pub-id-type="doi">10.1186/s13058-018-1042-7</pub-id>
<pub-id pub-id-type="pmid">30227879</pub-id>
</element-citation>
</ref>
<ref id="B34-cancers-12-00268">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH-NF-kappaB signalling pathway</article-title>
<source/>J. Cell Mol. Med.
          <year>2019</year>
<volume>23</volume>
<fpage>2689</fpage>
<lpage>2701</lpage>
<pub-id pub-id-type="doi">10.1111/jcmm.14168</pub-id>
<pub-id pub-id-type="pmid">30768878</pub-id>
</element-citation>
</ref>
<ref id="B35-cancers-12-00268">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ashmawy</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>El-Zamarany</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Khedr</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Abo-Saif</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Activation of EMT in colorectal cancer by MTDH/NF-kappaB p65 pathway</article-title>
<source/>Mol. Cell Biochem.
          <year>2019</year>
<volume>457</volume>
<fpage>83</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-019-03514-x</pub-id>
<pub-id pub-id-type="pmid">30825051</pub-id>
</element-citation>
</ref>
<ref id="B36-cancers-12-00268">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Huaier Granule extract inhibit the proliferation and metastasis of lung cancer cells through down-regulation of MTDH, JAK2/STAT3 and MAPK signaling pathways</article-title>
<source/>Biomed. Pharm.
          <year>2018</year>
<volume>101</volume>
<fpage>311</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.028</pub-id>
<pub-id pub-id-type="pmid">29499405</pub-id>
</element-citation>
</ref>
<ref id="B37-cancers-12-00268">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>AEG-1 participates in TGF-beta1-induced EMT through p38 MAPK activation</article-title>
<source/>Cell Biol. Int.
          <year>2013</year>
<volume>37</volume>
<fpage>1016</fpage>
<lpage>1021</lpage>
<pub-id pub-id-type="doi">10.1002/cbin.10125</pub-id>
<pub-id pub-id-type="pmid">23640911</pub-id>
</element-citation>
</ref>
<ref id="B38-cancers-12-00268">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noch</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bookland</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khalili</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Astrocyte-elevated gene-1 (AEG-1) induction by hypoxia and glucose deprivation in glioblastoma</article-title>
<source/>Cancer Biol.
          <year>2011</year>
<volume>11</volume>
<fpage>32</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.11.1.13835</pub-id>
</element-citation>
</ref>
<ref id="B39-cancers-12-00268">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Piao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFkappaB-dependent pathway</article-title>
<source/>BMC Cancer
          <year>2014</year>
<volume>14</volume>
<elocation-id>869</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-869</pub-id>
<pub-id pub-id-type="pmid">25417825</pub-id>
</element-citation>
</ref>
<ref id="B40-cancers-12-00268">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koh</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Unno</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Baicalein Suppresses Stem Cell-Like Characteristics in Radio-and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2</article-title>
<source/>Nutrients
          <year>2019</year>
<volume>11</volume>
<elocation-id>624</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu11030624</pub-id>
</element-citation>
</ref>
<ref id="B41-cancers-12-00268">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Inhibition of mitochondrial respiration and rapid depletion of mitochondrial glutathione by β-phenethyl isothiocyanate: Mechanisms for anti-leukemia activity</article-title>
<source/>Antioxid. Redox Signal.
          <year>2011</year>
<volume>15</volume>
<fpage>2911</fpage>
<lpage>2921</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2011.4170</pub-id>
<pub-id pub-id-type="pmid">21827296</pub-id>
</element-citation>
</ref>
<ref id="B42-cancers-12-00268">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agudelo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Parira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yndart</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Atluri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Samikkannu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Profile of class I histone deacetylases (HDAC) by human dendritic cells after alcohol consumption and in vitro alcohol treatment and their implication in oxidative stress: Role of HDAC inhibitors trichostatin A and mocetinostat</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0156421</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0156421</pub-id>
<pub-id pub-id-type="pmid">27249803</pub-id>
</element-citation>
</ref>
<ref id="B43-cancers-12-00268">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>S.Y.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine, reactive oxygen species and beyond</article-title>
<source/>Cancer Biol. Ther.
          <year>2010</year>
<volume>9</volume>
<fpage>109</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.9.2.10583</pub-id>
<pub-id pub-id-type="pmid">19949311</pub-id>
</element-citation>
</ref>
<ref id="B44-cancers-12-00268">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider-Poetsch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Eyler</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Merrick</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.O.</given-names>
</name>
</person-group>
<article-title>Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</article-title>
<source/>Nat. Chem. Biol.
          <year>2010</year>
<volume>6</volume>
<fpage>209</fpage>
<pub-id pub-id-type="doi">10.1038/nchembio.304</pub-id>
<pub-id pub-id-type="pmid">20118940</pub-id>
</element-citation>
</ref>
<ref id="B45-cancers-12-00268">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peitzsch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kunz-Schughart</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dubrovska</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Discovery of the cancer stem cell related determinants of radioresistance</article-title>
<source/>Radiother. Oncol.
          <year>2013</year>
<volume>108</volume>
<fpage>378</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.003</pub-id>
<pub-id pub-id-type="pmid">23830195</pub-id>
</element-citation>
</ref>
<ref id="B46-cancers-12-00268">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sreenivasan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Looso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Offermanns</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krüger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swiercz</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Quantitative analysis of the TNF-α-induced phosphoproteome reveals AEG-1/MTDH/LYRIC as an IKKβ substrate</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>6658</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms7658</pub-id>
<pub-id pub-id-type="pmid">25849741</pub-id>
</element-citation>
</ref>
<ref id="B47-cancers-12-00268">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ashmawy</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>El-Zamarany</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Khedr</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Abo-Saif</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Effect of modification of MTDH gene expression on colorectal cancer aggressiveness</article-title>
<source/>Gene
          <year>2019</year>
<volume>698</volume>
<fpage>92</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2019.02.069</pub-id>
<pub-id pub-id-type="pmid">30836117</pub-id>
</element-citation>
</ref>
<ref id="B48-cancers-12-00268">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshitomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohtsuka</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>66098</fpage>
<lpage>66111</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.19802</pub-id>
<pub-id pub-id-type="pmid">29029495</pub-id>
</element-citation>
</ref>
<ref id="B49-cancers-12-00268">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer</article-title>
<source/>Oncogene
          <year>2018</year>
<volume>37</volume>
<fpage>6166</fpage>
<lpage>6179</lpage>
<pub-id pub-id-type="doi">10.1038/s41388-018-0396-8</pub-id>
<pub-id pub-id-type="pmid">30002443</pub-id>
</element-citation>
</ref>
<ref id="B50-cancers-12-00268">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-like Cell Traits in Breast Cancer</article-title>
<source/>Cancer Res.
          <year>2015</year>
<volume>75</volume>
<fpage>3672</fpage>
<lpage>3680</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0930</pub-id>
<pub-id pub-id-type="pmid">26141861</pub-id>
</element-citation>
</ref>
<ref id="B51-cancers-12-00268">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition</article-title>
<source/>Cancer Sci.
          <year>2011</year>
<volume>102</volume>
<fpage>1151</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.01919.x</pub-id>
<pub-id pub-id-type="pmid">21371176</pub-id>
</element-citation>
</ref>
<ref id="B52-cancers-12-00268">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jutooru</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guthrie</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Chadalapaka</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pathi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Burghardt</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>U.H.</given-names>
</name>
<name>
<surname>Safe</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents</article-title>
<source/>Mol. Cell. Biol.
          <year>2014</year>
<volume>34</volume>
<fpage>2382</fpage>
<lpage>2395</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01602-13</pub-id>
<pub-id pub-id-type="pmid">24732804</pub-id>
</element-citation>
</ref>
<ref id="B53-cancers-12-00268">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Knudsen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells</article-title>
<source/>BMC Cancer
          <year>2014</year>
<volume>14</volume>
<elocation-id>591</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-591</pub-id>
<pub-id pub-id-type="pmid">25127663</pub-id>
</element-citation>
</ref>
<ref id="B54-cancers-12-00268">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.Q.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt/beta-catenin pathway</article-title>
<source/>Phytother. Res.
          <year>2018</year>
<volume>32</volume>
<fpage>2447</fpage>
<lpage>2455</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.6183</pub-id>
<pub-id pub-id-type="pmid">30159926</pub-id>
</element-citation>
</ref>
<ref id="B55-cancers-12-00268">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koschorke</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Faraci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chiodoni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Iorio</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Canese</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Lamolinara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iezzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ladomery</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment</article-title>
<source/>Cell Oncol.
          <year>2019</year>
<volume>6</volume>
<fpage>815</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1007/s13402-019-00464-w</pub-id>
<pub-id pub-id-type="pmid">31376137</pub-id>
</element-citation>
</ref>
<ref id="B56-cancers-12-00268">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciechanover</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The ubiquitin-proteasome proteolytic pathway</article-title>
<source/>Cell
          <year>1994</year>
<volume>79</volume>
<fpage>13</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(94)90396-4</pub-id>
<pub-id pub-id-type="pmid">7923371</pub-id>
</element-citation>
</ref>
<ref id="B57-cancers-12-00268">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawson</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>M.J.C.</given-names>
</name>
<name>
<surname>Vijaykumar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oualid</surname>
<given-names>F.E.</given-names>
</name>
<name>
<surname>Weerapana</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hedstrom</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Identification of deubiquitinase targets of isothiocyanates using SILAC-assisted quantitative mass spectrometry</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>51296</fpage>
<lpage>51316</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.17261</pub-id>
<pub-id pub-id-type="pmid">28881649</pub-id>
</element-citation>
</ref>
<ref id="B58-cancers-12-00268">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makeyev</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Maniatis</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Multilevel regulation of gene expression by microRNAs</article-title>
<source/>Science
          <year>2008</year>
<volume>319</volume>
<fpage>1789</fpage>
<lpage>1790</lpage>
<pub-id pub-id-type="doi">10.1126/science.1152326</pub-id>
<pub-id pub-id-type="pmid">18369137</pub-id>
</element-citation>
</ref>
<ref id="B59-cancers-12-00268">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Bartel</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Predicting effective microRNA target sites in mammalian mRNAs</article-title>
<source/>elife
          <year>2015</year>
<volume>4</volume>
<fpage>e05005</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id>
</element-citation>
</ref>
<ref id="B60-cancers-12-00268">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izzotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Larghero</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cartiglia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Longobardi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>V.E.</given-names>
</name>
<name>
<surname>De Flora</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung</article-title>
<source/>Carcinogenesis
          <year>2010</year>
<volume>31</volume>
<fpage>894</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgq037</pub-id>
<pub-id pub-id-type="pmid">20145010</pub-id>
</element-citation>
</ref>
<ref id="B61-cancers-12-00268">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranjan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kaushik</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Role of phytochemicals in cancer prevention</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>4981</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20204981</pub-id>
<pub-id pub-id-type="pmid">31600949</pub-id>
</element-citation>
</ref>
<ref id="B62-cancers-12-00268">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giallourou</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Rothwell</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Packham</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Commane</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Metabolic targets of watercress and PEITC in MCF-7 and MCF-10A cells explain differential sensitisation responses to ionising radiation</article-title>
<source/>Eur. J. Nutr.
          <year>2018</year>
<volume>58</volume>
<fpage>2377</fpage>
<lpage>2391</lpage>
<pub-id pub-id-type="doi">10.1007/s00394-018-1789-8</pub-id>
<pub-id pub-id-type="pmid">30066177</pub-id>
</element-citation>
</ref>
<ref id="B63-cancers-12-00268">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>Z.S.O.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cheaito</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mosallam</surname>
<given-names>E.S.M.</given-names>
</name>
<name>
<surname>Elbargeesy</surname>
<given-names>G.A.E.F.H.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>Q.P.</given-names>
</name>
</person-group>
<article-title>Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells</article-title>
<source/>J. Cell. Biochem.
          <year>2018</year>
<volume>119</volume>
<fpage>9006</fpage>
<lpage>9016</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.27157</pub-id>
<pub-id pub-id-type="pmid">30015387</pub-id>
</element-citation>
</ref>
<ref id="B64-cancers-12-00268">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palliyaguru</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Isothiocyanates: Translating the power of plants to people</article-title>
<source/>Mol. Nutr. Food Res.
          <year>2018</year>
<volume>62</volume>
<fpage>1700965</fpage>
<pub-id pub-id-type="doi">10.1002/mnfr.201700965</pub-id>
<pub-id pub-id-type="pmid">29468815</pub-id>
</element-citation>
</ref>
<ref id="B65-cancers-12-00268">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atwell</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Farris</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Vetto</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Naik</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Thuillier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy</article-title>
<source/>Cancer Prev. Res.
          <year>2015</year>
<volume>8</volume>
<fpage>1184</fpage>
<lpage>1191</lpage>
<pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-15-0119</pub-id>
<pub-id pub-id-type="pmid">26511489</pub-id>
</element-citation>
</ref>
<ref id="B66-cancers-12-00268">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method</article-title>
<source/>Methods
          <year>2001</year>
<volume>25</volume>
<fpage>402</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
<pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation>
</ref>
<ref id="B67-cancers-12-00268">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Quercetin suppresses cyr61-mediated multidrug resistance in human gastric adenocarcinoma ags cells</article-title>
<source/>Molecules
          <year>2018</year>
<volume>23</volume>
<elocation-id>209</elocation-id>
<pub-id pub-id-type="doi">10.3390/molecules23020209</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="cancers-12-00268-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Characteristics of radioresistant MDA-MB-231/IR cells. (<bold>a</bold>) Morphologies of MDA-MB-231 and MDA-MB-231/IR cells cultured as monolayers (100× magnification). (<bold>b</bold>) MDA-MB-231 and MDA-MB-231/IR cells cultured as mammospheres in complete MammoCult Human Medium for 10 days (100× magnification). (<bold>c</bold>) CD44<sup>+</sup>/CD24<sup>−</sup> population in MDA-MB-231/IR and MDA-MB-231 cells as analyzed by fluorescence-activated cell sorting (FACS). (<bold>d</bold>) ALDH<sup>+</sup> population assessed by the ALDEFLUOR assay kit, with DEAB used as the negative control. (<bold>e</bold>) Cancer stem cell (CSC) markers were analyzed by Western blotting; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as the mean ± standard deviation. (<bold>f</bold>) Invasion of MDA-MB-231/IR and MDA-MB-231 cells assessed by the Transwell cell invasion assay (100× magnification).</p>
</caption>
<graphic xlink:href="cancers-12-00268-g001"></graphic>
</fig>
<fig id="cancers-12-00268-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>ROS and GSH levels and expression of genes related to antioxidant effects in MDA-MB-231 and MDA-MB-231/IR cells. (<bold>a</bold>) ROS levels were evaluated after staining with H<sub>2</sub>DCFDA. (<bold>b</bold>) Total glutathione levels were measured by the GSH assay. (<bold>c</bold>) The expression of antioxidant-related genes was analyzed by real-time PCR; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g002"></graphic>
</fig>
<fig id="cancers-12-00268-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Analysis of metadherin (MTDH) expression in breast cancer patients. Correlation between MTDH expression and survival rate in total breast cancer patients (<bold>a</bold>) and triple negative breast cancer (TNBC) patients (<bold>b</bold>), as analyzed by Kaplan–Meier plotting. (<bold>c</bold>) MTDH expression in primary tumor and normal tissue in the The Cancer Genome Atlas (TCGA) breast cancer (BRCA) cohort. (<bold>d</bold>) Correlation between MTDH and CD44 expression, in the TCGA breast cancer (BRCA) cohort; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g003"></graphic>
</fig>
<fig id="cancers-12-00268-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Role of MTDH in regulating the CSC population in MDA-MB-231/IR cells. (<bold>a</bold>) Western blot analysis of MTDH in MDA-MB-231 and MDA-MB-231/IR cells. (<bold>b</bold>) Western blot analysis of MTDH, β-catenin, CD44, and Slug after knockdown by si-MTDH for 48 h. (<bold>c</bold>) Appearance of mammospheres after siRNA knockdown (100× magnification). (<bold>d</bold>) ALDH<sup>+</sup> population obtained by the ALDEFLUOR assay kit, with DEAB used as a negative control. (<bold>e</bold>) ROS levels measured by FACS analysis and H<sub>2</sub>DCFDA staining. (<bold>f</bold>) The CD44<sup>+</sup> population, as assessed by FACS analysis; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g004"></graphic>
</fig>
<fig id="cancers-12-00268-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>PEITC reduces cell viability in MDA-MB-231/IR cells by increasing ROS levels. (<bold>a</bold>) Cell viability was assessed by the MTT assay. (<bold>b</bold>) ROS levels were analyzed after staining with H<sub>2</sub>DCFDA. (<bold>c</bold>) Total GSH levels were measured by a GSH assay. (<bold>d</bold>) Pre-treatment with NAC (10 mM) helped maintain the viability of MDA-MB-231/IR cells, as assessed by the MTT assay; * <italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g005"></graphic>
</fig>
<fig id="cancers-12-00268-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>Effects of PEITC on stemness in MDA-MB-231/IR cells. (<bold>a</bold>) Mammospheres were cultured in complete MammoCult Human Medium (100× magnification). (<bold>b</bold>) CD44<sup>+</sup>/CD24<sup>−</sup> populations were assessed by FACS analysis after incubation with PEITC (0, 5, 10, 15, or 20 μM) for 24 h. (<bold>c</bold>) The ALDH<sup>+</sup> population was examined using the ALDEFLUOR assay kit, with DEAB used as a negative control; cells were treated with PEITC (0 or 5 μM) for 24 h. (<bold>d</bold>) Cell migration was determined by the wound healing assay; cells were treated with PEITC (0 or 5 µM) for 24 or 48 h (100× magnification). (<bold>e</bold>) Invasive cells were stained with crystal violet after treatment with PEITC (0 or 5 µM) for 24 h (100× magnification). (<bold>f</bold>) Western blot analysis of Slug after incubation of cells with PEITC (0, 1.25, 2.5, or 5 μM) for 24 h; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g006"></graphic>
</fig>
<fig id="cancers-12-00268-f007" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<p>PEITC targets MTDH and CSC markers in MDA-MB-231/IR cells. (<bold>a</bold>) The levels of MTDH and CSC markers were assessed by Western blotting following PEITC (0, 10 μM) treatment. (<bold>b</bold>) NAC pre-treatment helped maintain the expression of MTDH and CSC markers; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g007"></graphic>
</fig>
<fig id="cancers-12-00268-f008" orientation="portrait" position="float">
<label>Figure 8</label>
<caption>
<p>PEITC regulates MTDH post-transcriptionally. (<bold>a</bold>) Real-time PCR analysis of MTDH following PEITC treatment (10 µM for 6, 12, or 24 h). (<bold>b</bold>) Western blot analysis was performed to analyze MTDH expression following PEITC exposure (10 µM for 6, 12, or 24 h), similar to <xref ref-type="fig" rid="cancers-12-00268-f007">Figure 7</xref>a. (<bold>c</bold>) Western blot analysis of the MTDH protein expression following co-treatment with PEITC (20 µM) and cycloheximide (100 μg/mL) for 30, 60, or 120 min; <bold>*</bold>
<italic>p</italic> &lt; 0.05; results are presented as mean ± standard deviation.</p>
</caption>
<graphic xlink:href="cancers-12-00268-g008"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>